Cambridge Healthtech Institute’s 12th Annual

Oligo Discovery & Clinical Development

Advancing Nucleic Acids through Innovative Design, Delivery, and Development

March 17-18, 2027

Cambridge Healthtech Institute’s 12th Annual Oligo Discovery & Clinical Development conference brings together leading voices from biotech, pharma, and academia to accelerate oligonucleotide therapeutics from early discovery into the clinic. From target identification, modality selection, sequence design, and chemistry to emerging therapeutic mechanisms, the program will showcase innovations shaping the next generation of oligonucleotides. Key sessions will explore non-conjugate delivery platforms, extrahepatic delivery, tissue targeting, cellular uptake, and endosomal escape. Attendees will gain insights into strengthening preclinical-to-clinical translation through biomarkers, PK/PD, target engagement, and optimized clinical development strategies. The conference will also examine advances in RNA editing and gene editing, AI- and ML-enabled development, safety and toxicity, clinical trial design, and collaborative approaches that can accelerate the delivery of safe and effective oligonucleotide therapeutics to patients.

Coverage will include, but is not limited to:

Advancing oligonucleotide discovery through target identification, modality selection, sequence design, and chemistry
Exploring emerging therapeutic modalities and mechanisms of action
Advancing non-conjugate delivery using LNPs, exosomes, and emerging delivery platforms
Innovating extrahepatic delivery, tissue targeting, cellular uptake, and endosomal escape
Accelerating preclinical-to-clinical translation through biomarkers, PK/PD, and target engagement
Sharing preclinical and clinical case studies across CNS, liver, oncology, ocular, and rare diseases
Advancing RNA editing, gene editing, base editing, prime editing, and CRISPR technologies
Exploring RNA interference (RNAi) for obesity and cardiometabolic diseases
Leveraging AI and ML across oligonucleotide discovery, delivery, and development
Addressing safety, toxicity, immunostimulation, and off-target effects
Optimizing clinical trial design, patient selection, endpoints, and regulatory strategies
Building strategic collaborations across pharma, biotech, academia, and patient organizations

The deadline for priority consideration is September 4, 2026.

Submit a Proposal »

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

Opportunities for Participation: